LEROCHOL China Review: PCSK9 Cholesterol Drug

What Is LEROCHOL And Why Does The China Review Matter?

LEROCHOL, also known as lerodalcibep, is designed to lower low-density lipoprotein cholesterol, or LDL-C, by targeting PCSK9, a liver-related protein that influences how efficiently LDL receptors remove cholesterol from the bloodstream. China’s NMPA acceptance of the biologics license application means regulators have agreed to formally review the submission; it does not mean the medicine has been approved.

The review matters because LDL-C remains one of the most important modifiable drivers of atherosclerotic cardiovascular disease. World Health Organization data consistently identify cardiovascular disease as the leading global cause of death, and decades of lipid research support LDL-C reduction as a central prevention strategy for heart attack and stroke.

How Do PCSK9 Medicines Lower LDL Cholesterol?

PCSK9 normally promotes the breakdown of LDL receptors on liver cells. When PCSK9 is inhibited, more LDL receptors remain available to pull LDL cholesterol out of circulation. This mechanism is different from statins, which primarily reduce cholesterol synthesis in the liver, making PCSK9-targeting therapies useful as add-on treatment for some patients who need deeper LDL-C lowering.

Large outcomes trials of established PCSK9 monoclonal antibodies, including evolocumab and alirocumab, have shown that intensive LDL-C lowering can reduce major cardiovascular events in high-risk patients already receiving standard therapy. Those trials do not automatically prove identical outcome benefits for every new PCSK9-targeting product, but they provide strong biological and clinical context for why regulators, clinicians, and patients are watching this class closely.

Who Could Benefit If LEROCHOL Is Approved?

If approved, LEROCHOL would likely be considered within the broader framework of lipid guidelines: lifestyle measures first, statins as foundational therapy for many patients, and additional agents when LDL-C remains above individualized targets. People with heterozygous familial hypercholesterolemia, established atherosclerotic cardiovascular disease, or very high baseline LDL-C often need combination treatment to reach recommended goals.

For patients, the practical questions will include eligibility, injection schedule, safety monitoring, affordability, and whether local guidelines position the drug before or after other non-statin options such as ezetimibe, bempedoic acid, inclisiran, or existing PCSK9 antibodies. Until the NMPA completes its review, patients should not interpret the application acceptance as a reason to change prescribed cholesterol treatment without medical advice.